LUZU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUZU (LUZU).
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption; absorbed fraction undergoes hepatic metabolism primarily via CYP3A4 and CYP2C19 |
| Excretion | Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route. |
| Half-life | The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application. |
| Protein binding | >99% bound to plasma proteins, primarily albumin; the high protein binding limits systemic distribution. |
| Volume of Distribution | After topical application, the volume of distribution is not clinically meaningful due to minimal systemic absorption; following intravenous administration in animal studies, Vd is approximately 1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Following topical application, systemic bioavailability is <0.1% due to low percutaneous absorption; oral bioavailability is not clinically relevant as the drug is not administered orally. |
| Onset of Action | For topical application: Clinical improvement is observed within 1 week of treatment initiation; mycological cure may be seen as early as 2 weeks. |
| Duration of Action | The duration of action extends beyond the treatment period due to prolonged skin retention; for tinea pedis, a 2-week treatment course results in clinical cure rates at 3-4 weeks post-treatment; for tinea cruris/corporis, a 1-week course similarly provides sustained effect. |
| Molecular Weight | 326.39 |
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No dosage adjustment required for mild to severe hepatic impairment (Child-Pugh A, B, C). |
| Pediatric use | Approved for use in patients 12 years and older with same dosing as adults. Safety and efficacy in children <12 years not established. |
| Geriatric use | No specific dose adjustments; use same dosing as younger adults based on clinical studies. |
| 1st trimester | Avoid use during first trimester due to potential teratogenic effects observed in animal studies. There are no adequate human studies. |
| 2nd trimester | Use only if potential benefit justifies risk to fetus. Limited data suggest increased risk of low birth weight. |
| 3rd trimester | Avoid use near term due to risk of neonatal respiratory depression and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for LUZU (LUZU).
| Placental transfer | Crosses placenta readily; fetal plasma levels approximately 50-80% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts. Monitor infant for sedation and respiratory depression. Consider alternative agents. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to LUZU or any componentSevere hepatic impairmentAcute narrow-angle glaucoma
| Precautions | For external use only; avoid contact with eyes, mouth, or vagina; discontinue if hypersensitivity or irritation occurs; use during pregnancy only if clearly needed; not evaluated for treatment of onychomycosis or scalp infections |
| Food/Dietary | No known food interactions with topical luliconazole. Systemic absorption is minimal, so dietary restrictions are not required. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, topical administration of luliconazole during organogenesis resulted in embryofetal toxicity at systemic exposures less than the maximum recommended human dose. Risk cannot be ruled out. First trimester: Use only if potential benefit justifies potential risk. Second and third trimesters: Limited data; avoid if possible. |
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond standard obstetric care. Observe for local irritation or allergic reactions at application site. |
| Fertility Effects | No human studies on fertility. In animal studies, no impairment of fertility was observed in male or female rats at oral doses up to 50 mg/kg/day. |
| Luliconazole is an azole antifungal for topical use only. It has broad-spectrum activity against dermatophytes, Candida, and Malassezia. Its unique structure allows once-daily application for most indications. Avoid occlusive dressings unless directed. Monitor for local irritation; discontinue if hypersensitivity occurs. Not for ophthalmic, oral, or intravaginal use. |
| Patient Advice | Apply a thin layer to affected and surrounding skin once daily for the prescribed duration. · Wash hands before and after application unless treating the hands. · Do not cover treated area with bandages or dressings unless directed by your healthcare provider. · Avoid contact with eyes, mouth, or open wounds. If accidental contact occurs, rinse thoroughly with water. · Complete the full course of treatment even if symptoms improve. · Inform your doctor if condition worsens or does not improve after 4 weeks of treatment. · Keep out of reach of children. For external use only. |